Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
The primary active compound in this plant is more potent than LSD.
Using psychedelics to treat chronic pain is understudied yet full of potential.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Understanding brain morphology differences may prove essential for creating effective psychedelic drug formulations.
Pain was inhibited by an α2-adrenoceptor antagonist and reduced by an α1-adrenoceptor antagonist. Opioid receptors may also be involved in the effects.
GPCRs play a major role in the psychedelic effect. They also have qualities that make them ideal targets for drug development.